Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs

OBJECTIVES: To examine the long-term safety of intravenous (IV) abatacept treatment in Japanese patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) or other conventional or biologic disease-modifying antirheumatic drugs. METHODS: This Phase III, open-label, long-...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Matsubara, Tsukasa, Urata, Yukitomo, Suematsu, Eiichi, Ohta, Shuji, Honjo, Shigeru, Abe, Tohru, Yamamoto, Ami, Miyasaka, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162652/
https://www.ncbi.nlm.nih.gov/pubmed/24754273
http://dx.doi.org/10.3109/14397595.2014.899179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162652/
https://www.ncbi.nlm.nih.gov/pubmed/24754273
http://dx.doi.org/10.3109/14397595.2014.899179

Ejemplares similares